


Claims:

1. A compound of Formula (I):



or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, isomer, or tautomer thereof,
wherein:

R^1 is $-OR^5$;

R⁵ is -C₁-C₆alkyl;

R⁶ is phenyl optionally substituted with one or more R¹⁰;

R^{10} is each independently, at each occurrence, $-C_1-C_6$ alkyl, $-C_2-C_6$ alkenyl, $-C_2-C_6$ alkynyl, $-C_3-C_8$ cycloalkyl, $-C_4-C_8$ cycloalkenyl, heterocyclyl, heteroaryl, aryl, $-OH$, halogen, $-NO_2$, $-CN$, $-NH_2$, $-OC_1-C_6$ alkyl, $-OC_3-C_6$ cycloalkyl, $-O$ aryl, $-O$ heteroaryl, $-NHC_1-C_6$ alkyl, $-N(C_1-C_6alkyl)_2$, $-S(O)_2NH(C_1-C_6alkyl)$, $-S(O)_2N(C_1-C_6alkyl)_2$, $-S(O)_2C_1-C_6alkyl$, $-C(O)C_1-C_6alkyl$, $-C(O)NH_2$, $-C(O)NH(C_1-C_6alkyl)$, $-C(O)N(C_1-C_6alkyl)_2$, $-C(O)OC_1-C_6alkyl$, $-N(C_1-C_6alkyl)SO_2C_1-C_6alkyl$, $-S(O)(C_1-C_6alkyl)$, $-S(O)N(C_1-C_6alkyl)_2$, or $-N(C_1-C_6alkyl)S(O)(C_1-C_6alkyl)$, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more $-R^{12}$;

wherein any two R¹⁰ when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;

wherein any two R¹⁰ when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;

R¹² is independently, at each occurrence, -C₁-C₆alkyl, -C₂-C₆alkenyl, -C₂-C₆alkynyl, -C₃-C₈cycloalkyl, -C₄-C₈cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO₂, -CN, -NH₂, -OC₁-C₆alkyl, -NHC₁-C₆alkyl, -N(C₁-C₆alkyl)₂, -S(O)₂NH(C₁-C₆alkyl), -S(O)₂N(C₁-C₆alkyl)₂, -S(O)₂C₁-C₆alkyl, -C(O)C₁-C₆alkyl, -C(O)NH₂, -C(O)NH(C₁-C₆alkyl),

$-\text{C}(\text{O})\text{N}(\text{C}_1\text{-C}_6\text{alkyl})_2$, $-\text{C}(\text{O})\text{OC}_1\text{-C}_6\text{alkyl}$, $-\text{N}(\text{C}_1\text{-C}_6\text{alkyl})\text{SO}_2\text{C}_1\text{-C}_6\text{alkyl}$, $-\text{S}(\text{O})(\text{C}_1\text{-C}_6\text{alkyl})$, $-\text{S}(\text{O})\text{N}(\text{C}_1\text{-C}_6\text{alkyl})_2$, or $-\text{N}(\text{C}_1\text{-C}_6\text{alkyl})\text{S}(\text{O})(\text{C}_1\text{-C}_6\text{alkyl})$.

2. The compound of claim 1 or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, isomer, or tautomer thereof, wherein

R^5 is $-\text{C}_1\text{-C}_3\text{alkyl}$;

R^{10} is each independently, at each occurrence halogen or $-\text{OC}_1\text{-C}_6\text{alkyl}$, $-\text{OC}_3\text{-C}_6\text{cycloalkyl}$, $-\text{Oaryl}$, $-\text{Oheteroaryl}$, wherein each alkyl, cycloalkyl, aryl or heteroaryl is optionally substituted with one or more $-\text{R}^{12}$;

R^{12} is halogen.

3. The compound of any one of claims 1-2, or a pharmaceutically acceptable salt thereof, wherein R^5 is methyl.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein at least one R^{10} is halogen.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein at least one R^{10} is $-\text{OC}_1\text{-C}_6\text{alkyl}$.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein any two R^{10} when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl.


7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein any two R^{10} when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl.


8. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein R^6 is phenyl optionally substituted with one or two R^{10} and each R^{10} is independently, at each occurrence, halogen or $-\text{OC}_1\text{-C}_6\text{alkyl}$, wherein the $-\text{OC}_1\text{-C}_6\text{alkyl}$ is optionally substituted with halogen.


9. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein each R^{10} is independently, at each occurrence halogen or $-\text{OC}_1\text{alkyl}$ optionally substituted with one or more halogen.

10. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein each R^{12} is independently, at each occurrence, fluoro.


11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from









12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure



13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure



14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure



15. A pharmaceutical composition comprising a compound of any one of claims 1-14, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.